BRPI0514871A - cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila - Google Patents

cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila

Info

Publication number
BRPI0514871A
BRPI0514871A BRPI0514871-5A BRPI0514871A BRPI0514871A BR PI0514871 A BRPI0514871 A BR PI0514871A BR PI0514871 A BRPI0514871 A BR PI0514871A BR PI0514871 A BRPI0514871 A BR PI0514871A
Authority
BR
Brazil
Prior art keywords
amino
cyanoethenyl
dimethylphenyl
pyrimidinyl
benzonitrile hydrochloride
Prior art date
Application number
BRPI0514871-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Theodoor Agnes Stevens
Jozef Peeters
Roger Petrus Gerebe Vandecruys
Alfred Elisabeth Stappers
Alex Herman Copmans
Original Assignee
Janssen Pharmaceutica Nv
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38091637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv, Tibotec Pharm Ltd filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2005/054342 external-priority patent/WO2006024668A1/en
Publication of BRPI0514871A publication Critical patent/BRPI0514871A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hybrid Cells (AREA)
BRPI0514871-5A 2004-09-02 2005-09-02 cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila BRPI0514871A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101467 2005-02-25
PCT/EP2005/054342 WO2006024668A1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile

Publications (1)

Publication Number Publication Date
BRPI0514871A true BRPI0514871A (pt) 2008-06-24

Family

ID=38091637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514871-5A BRPI0514871A (pt) 2004-09-02 2005-09-02 cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila

Country Status (21)

Country Link
EP (1) EP1632232B3 (enExample)
JP (1) JP4912309B2 (enExample)
CN (1) CN104586850A (enExample)
AT (1) ATE508748T1 (enExample)
BR (1) BRPI0514871A (enExample)
CY (3) CY1112249T1 (enExample)
DK (1) DK1632232T6 (enExample)
EA (1) EA013686B1 (enExample)
ES (1) ES2371442T7 (enExample)
FR (2) FR16C1023I1 (enExample)
HK (1) HK1210029A1 (enExample)
HU (2) HUS1600061I1 (enExample)
IL (1) IL181650A (enExample)
LT (2) LTC1632232I2 (enExample)
ME (1) ME01246B (enExample)
MX (1) MX2007002595A (enExample)
NI (1) NI200700068A (enExample)
NO (3) NO340654B1 (enExample)
PT (1) PT1632232E (enExample)
RS (1) RS51923B2 (enExample)
SI (1) SI1632232T1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
SI1981506T1 (sl) 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ES2524408T5 (es) * 2010-11-19 2022-04-25 Gilead Sciences Inc Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
AP2013006779A0 (en) * 2011-04-15 2013-03-31 Emcure Pharmaceuticals Ltd An improved rilpivirine process
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) * 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
WO2013153161A2 (en) * 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
GR1008965B (el) * 2015-12-02 2017-02-28 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
CN110191704A (zh) * 2016-10-24 2019-08-30 爱尔兰詹森科学公司 可分散组合物
JP7287906B2 (ja) * 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307543B1 (en) * 1998-09-10 2001-10-23 Silicon Image, Inc. Bi-directional data transfer using two pair of differential lines as a single additional differential pair
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2003266413B2 (en) * 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EA011164B1 (ru) * 2003-02-07 2009-02-27 Янссен Фармацевтика Н. В. Производные пиримидина для профилактики вич-инфекции

Also Published As

Publication number Publication date
ME01246B (me) 2013-06-20
RS51923B2 (sr) 2022-05-31
HUS1600060I1 (hu) 2017-01-30
NO2017065I1 (no) 2017-11-21
CY1112249T1 (el) 2015-12-09
PT1632232E (pt) 2011-08-02
JP2008511592A (ja) 2008-04-17
SI1632232T1 (sl) 2011-09-30
LTPA2016043I1 (lt) 2017-01-10
MX2007002595A (es) 2007-04-25
DK1632232T6 (da) 2022-04-19
HK1210029A1 (en) 2016-04-15
NO20071745L (no) 2007-04-02
NI200700068A (es) 2016-09-29
FR16C1025I2 (fr) 2025-11-21
LTC1632232I2 (lt) 2024-09-10
DK1632232T3 (da) 2011-08-22
JP4912309B2 (ja) 2012-04-11
IL181650A0 (en) 2007-07-04
ATE508748T1 (de) 2011-05-15
LTPA2016042I1 (lt) 2017-01-10
EP1632232A1 (en) 2006-03-08
FR16C1023I1 (fr) 2017-02-03
CY2016050I1 (el) 2017-07-12
NO2017063I1 (no) 2017-11-21
EA013686B1 (ru) 2010-06-30
NO340654B1 (no) 2017-05-22
EA200700536A1 (ru) 2007-08-31
ES2371442T3 (es) 2012-01-02
FR16C1025I1 (fr) 2017-02-03
CN104586850A (zh) 2015-05-06
IL181650A (en) 2012-08-30
RS51923B (sr) 2012-02-29
ES2371442T7 (es) 2022-05-12
CY2016051I1 (el) 2017-07-12
EP1632232B3 (en) 2022-03-30
EP1632232B1 (en) 2011-05-11
HUS1600061I1 (hu) 2017-01-30

Similar Documents

Publication Publication Date Title
BRPI0514871A (pt) cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
AR063305A1 (es) Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-[[metil(1-metiletil)amino]sulfonil]benzamida
DOP2011000360A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4((2-amino-4-metil-6-(pentilamino) primidin-5-ii)metil) fenil) acetato de 4-(dimetilamino) butilo
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
ECSP109890A (es) Particulas de un antagonista de crth2
BRPI0514731A (pt) derivados de pirimidina
PL1632232T3 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
DE602004016761D1 (de) Tablettenformulierungen von venlafaxin mit verzögerter freisetzung
UA92467C2 (ru) Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CR9032A (es) Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo
TW200740756A (en) Potentiator of glutamate receptors
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TH151366A (th) องค์ประกอบ ซึ่งประกอบด้วย s-[2-([[1-(2-เอทธิลบิวทิล)ไซโคลเฮกซิล]-คาร์บอนิล]อะมิโน)-ฟีนิล]-2-เมทธิลโพรเพนไธโอเอต และครอสคาร์เมลโลส โซเดียม

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN PHARMACEUTICA N.V. (BE)

Free format text: TRANSFERIDO DE: TIBOTEC PHARMACEUTICALS LTD.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: REFERENTE A RPI NO 2051 DE 27/04/2010.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/505 (2006.01), A61P 31/18 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]